PMS Registry
Company Name
Pfizer Inc.
Protocol Number
Title of Study
Post-Marketing Surveillance study to observe INLYTA® treatment dosing pattern, safety and effectiveness in Taiwan real world routine practice
Primary Objective
The primary objective of this registry is to monitor the dose adjustment of INLYTA® in real world routine practice.
The secondary objectives include safety profile, objective response rate, and progression-free rate in real world routine practice.
Number of Sites
Period of Study
From:Dec. 1, 2015 to:Dec. 31, 2017
Number of Patients
NA, Given this is a registry rather than a clinical research of comparison, the sample size is limited by actual patients fulfill the inclusion criteria and without any situation listed in exclusion criteria treated in Taiwan during the registry period; a calculated sample number is not applicable for present setting.人
IRB Approval Date
Nov. 3, 2015
Publication Plan / Date
Dec. 31, 2018